Kare Schultz to head pharmaceutical company Teva

The new president and CEO of the pharmaceutical company Teva, one of whose members is the Leskovac-based plant Zdravlje, will be Kare Shcultz, Teva reported on September 12.

Kare Schultz, as stated, has nearly thirty years of experience in jobs in the global pharmaceutical and healthcare sector.

Headquartered in Israel, Teva is the biggest global producer of generic medical drugs. It sells its products in 60 markets. The company's net income amounted to USD 21.9 billion in 2016.

In the field of specialty medical drugs, Teva is the leading company in the world in innovative multiple sclerosis treatment and late-stage development programs for other central nervous system disorders, including disorders related to motion, migraines and neurodegenerative conditions. Teva has a rich portfolio of products for respiratory diseases. The company integrates generic and specialty possibilities in order to find new ways of meeting patients' needs, combining the capacities of drug development with the development of devices, services and technology, the press release adds.

Teva took over Actavis, which had included Zdravlje Leskovac, last summer.

Teva Pharmaceutical Industries Ltd Izrael

Zdravlje a.d. Leskovac

Actavis Beograd

Kare Schultz

Actavis

medical drug production

production of generic medical drugs

pharmaceutical industry

medical drugs

generic drugs

innovative drugs

multiple sclerosis

drugs for multiple sclerosis

speciality drugs

central nervous system diseases